


글로벌 제약사 파이프라인 분석

- Boehringer Ingelheim -

2022. 11.


국가신약개발사업단

• 질환별 파이프라인



질환분야	개수	비중
Oncology	17	48%
Cardiovascular	6	13%
Respiratory	5	11%
Immunology	5	11%
Neuroscience	5	11%
Renal	3	7%
Metabolic	2	4.5%
Ophthalmology	2	4.5%
합계	45개	100%

• 물질별 파이프라인



물질	개수	비중
Small molecules	15	33%
N/A(Not Applicable)	10	22%
Antibody	9	20%
Peptide	5	11%
Vaccine	2	5%
Protein	2	5%
Virus	1	2%
ADC	1	2%
합계	45개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
1	Cardiovascular	Phase 3	BI-10773	Jardiance	empagliflozin	Heart Failure port MI	Small molecules	SGLT2	SGLT2 inhibitor	Mono	-
2	Cardiovascular	Phase 1				cardiovascular diseases	Antibody	Angiotensin	Angiotensin antibody	Mono	-
3	Cardiovascular	Phase 1				cardiovascular diseases	N/A	N/A	Food intake regulator	Mono	-
4	Cardiovascular	Phase 1				cardiovascular diseases	N/A	N/A	Hemodynamic Modulator	Mono	-
5	Cardiovascular	Phase 1				cardiovascular diseases	Protein	GLP-1, FGF21	GLP-1/FGF21 agonist	Mono	-
6	Cardiovascular	Phase 1				cardiovascular diseases	Small molecules	Transient receptor potential channel	Transient receptor potential channel inhibitor	Mono	-
7	Immunology	Registration	BI655130		spesolimab	Generalized pustular psoriasis	Peptide	IL-36	IL-36 antagonist	Mono	-
8	Immunology	Phase 2	BI706321			Crohn's disease	N/A	N/A	Kinase inhibitor	Mono	-
9	Immunology	Phase 2	BI655130		spesolimab	Hidradenitis suppurativa	Peptide	IL-36	IL-36 antagonist	Mono	-
10	Immunology	Phase 2	BI655130		spesolimab	Palmoplantar Pustulosis	Peptide	IL-36	IL-36 antagonist	Mono	-
11	Immunology	Phase 1				Autoimmune diseases	Antibody	PD-1	PD-1 antibody	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
12	Metabolic	Phase 2	BI456906			Obesity	Peptide	GCGR, GLP-1	GCGR, GLP-1 agonist	Mono	Zealand Pharma
13	Metabolic	Phase 2	BI456906			Non-alcoholic steatohepatitis (NASH)	Peptide	GCGR, GLP-1	GCGR, GLP-1 agonist	Mono	Zealand Pharma
14	Neuroscience	Phase 3	BI425809		Iclepertin	Cognitive Impairment Associated with Schizophrenia	Small molecules	GlyT1	GlyT1 inhibitor	Mono	-
15	Neuroscience	Phase 2	BI1358894			Borderline personality disorder	Small molecules	TRPC 4/5	TRPC 4/5 inhibitor	Mono	-
16	Neuroscience	Phase 2	BI1358894			Major depressive disorder	Small molecules	TRPC 4/5	TRPC 4/5 inhibitor	Mono	-
17	Neuroscience	Phase 2	BI1358894			Post traumatic stress disorder	Small molecules	TRPC 4/5	TRPC 4/5 inhibitor	Mono	-
18	Neuroscience	Phase 1				CNS disorders	Small molecules	Phosphodiesterase	Phosphodiesterase Inhibitor	Mono	-
19	Oncology	Phase 2	BI907828			Dedifferentiated liposarcoma	Small molecules	MDM2-p53	MDM2-p53 antagonist	Mono	-
20	Oncology	Phase 1				Cancers	Antibody	B7-H6, CD3	Bispecific antibody (B7-H6, CD3)	Mono	-
21	Oncology	Phase 1				Cancers	Antibody	CD137, FAP	Bispecific antibody (CD137, FAP)	Mono	-
22	Oncology	Phase 1				Cancers	Antibody	DLL3, CD3	Bispecific antibody (DLL3, CD3)	Mono	-
23	Oncology	Phase 1			exabenlimab	Cancers	Antibody	PD-1	PD-1 antibody	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
24	Oncology	Phase 1				Cancers	Vaccine	N/A	Heterologous prime boost vaccine	Mono	-
25	Oncology	Phase 1				Cancers	N/A	HER2	HER2 exon20 inhibitor	Mono	-
26	Oncology	Phase 1				Cancers	Vaccine	KISIMA	KISIMA cancer vaccine	Mono	-
27	Oncology	Phase 1				Cancers	Small molecules	KRAS	KRAS inhibitor	Mono	-
28	Oncology	Phase 1				Cancers	Small molecules	MDM2-p53	MDM2-p53 antagonist	Mono	-
29	Oncology	Phase 1				Cancers	Small molecules	KRAS, SOS1	pan KRAS, SOS1 inhibitor	Mono	-
30	Oncology	Phase 1				Cancers	ADC	ROR1	ROR1 ADC	Mono	-
31	Oncology	Phase 1				Cancers	Small molecules	MEK	MEK inhibitor	Mono	-
32	Oncology	Phase 1				Cancers	Small molecules	STING	STING agonist	Mono	-
33	Oncology	Phase 1				Cancers	Antibody	SIRP1 α	SIRP1 α antagonist	Mono	-
34	Oncology	Phase 1				Cancers	Antibody	TRAILR2, CDH17	TRAILR2/CDH17 antibody	Mono	-
35	Oncology	Phase 1	VSV-GP			Cancers	Virus	N/A	Oncolytic virus	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	Mono/병용	파트너
36	Ophthalmology	Phase 2	BI764524			Diabetic macular ischemia	N/A	N/A	Ischemia modulator	Mono	-
37	Ophthalmology	Phase 1				Retinal diseases	Antibody	N/A	Ischemia modulator	Mono	-
38	Renal	Phase 3	BI-10773	Jardiance	empagliflozin	Chronic kidney disease	Small molecules	SGLT2	SGLT2 inhibitor	Mono	-
39	Renal	Phase 2	BI685509			Chronic kidney disease	N/A	Soluble guanylate cyclase(sGC)	sGC activator	Mono	-
40	Renal	Phase 2	BI690517			Chronic kidney disease	N/A	N/A	Hemodynamic modulator	Mono	-
41	Respiratory	Phase 3			alteplase	Covid-19 induced acute respiratory syndrome	Protein	Plasminogen	Tissue plasminogen activator	Mono	Genentech
42	Respiratory	Phase 2	BI1015550			Idiopathic pulmonary fibrosis	Small molecules	PDE48	PDE48 inhibitor	Mono	-
43	Respiratory	Phase 1				Respiratory diseases	N/A	Cysteine protease	Cysteine protease inhibitor	Mono	-
44	Respiratory	Phase 1				Respiratory diseases	N/A	Leukocyte protease	Leukocyte protease inhibitor	Mono	-
45	Respiratory	Phase 1				Respiratory diseases	N/A	Lysophospholipase	Lysophospholipase inhibitor	Mono	-

자료: Boehringer Ingelheim 홈페이지, BioCentury, GlobalData